Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Tsao is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2001 - 2004
Indiana University School of MedicineResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2028
TX State Medical License 2001 - 2028
MS State Medical License 2023 - 2027
TN State Medical License 2023 - 2027
AL State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013, 2015
Clinical Trials
Publications & Presentations
PubMed
- Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in aFusion-Positive NSCLC Real-World Cohort: A Brief Report.Alvaro Guimaraes Paula, Ximeng Liu, Amirali Karimi, Kyle Concannon, Simon Heeke
JTO Clinical and Research Reports. 2026-08-01 - Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription.Ruitao Lin, Mei Chen, Xiaodong Zhang, Tianlin Xu, Ting Xu
International Journal of Radiation Oncology, Biology, Physics. 2026-07-01 - Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non-Small Cell Lung Cancers from the PHAROS Study.Gregory J Riely, Jean-François Martini, Norberto Pantoja Galicia, Brian Tunquist, Keith Wilner
Cancer Research Communications. 2026-07-01
Lectures
- Changing the Concurrent Chemotherapy-Radiation Paradigm: Can We Replace Chemotherapy with...ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothel...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- Systemic treatment for unresectable malignant pleural mesotheliomaTsao AS, Vogelzang N
http://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma
UpToDate, Wolters Kluwer Health - 2013-04-15
Press Mentions
ECOG-ACRIN Research Highlights at ASCO 2022May 27th, 2022- New Mesothelioma Immunotherapy Clinical Trial Opens at MD AndersonMay 11th, 2022
- Raffit Hassan, MD, on Immunotherapy's Inroads in Malignant Pleural MesotheliomaMay 6th, 2022
Grant Support
- UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS) UG1UNIVERSITY OF TX MD ANDERSON CAN CTR2019–2032
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
